CHC Healthcare Group

Meeting Minutes for 2025 Annual Shareholders' Meeting

- Date: Wednesday, June 4, 2025 at 09:00 a.m.
- Place: No.88, Xing'ai Rd., Neihu Dist., Taipei City, Taiwan
  (The Company's conference room on the second floor)
- Shareholders present:
  CHC's total outstanding shares are 185,711,966 shares. The shareholders and proxies of shareholders present in the meeting represent 102,930,281 shares, including 53,374,937 shares represented by shareholders participating through electronic means. The presence of the shareholders and proxies of shareholders account for 55.42% of the total of 185,711,966 outstanding shares entitled to attend the Meeting.
- Chair: Mr. Pei-Lin, Lee, Chairman
- Minutes taker: Chia-Wen, Wang
- Board members present:
  Mr. Pei-Lin, Lee, Chairman
  Mr. Tien-Ying, Lee, Vice chairman
  Mr. Ming-Liang, Kao, Independent director / Convener of audit committee
  Mr. Geng-Wang, Liaw, Independent director / Convener of remuneration committee
  Mr. Yung-Shun, Chuang, Director
- In attendance:
  Mr. Ming-Lun, Lee, General manager
  Ms. Yi-Chun, Chen, Chief financial officer
  Mr. Sheng-Wei, Teng, Independent auditor, PricewaterhouseCoopers (PwC) Taiwan
  Ms. Wen-Ling, Tsai, Attorney, GuoJu Law Firm

Ⅰ. Commencement: The aggregate shareholdings of the shareholders and proxies of shareholders present constitute a quorum. Chair of the Meeting calls the Meeting to order.

Ⅱ. Chair's Address: Dear shareholders, thank you for visiting 2025 Annual Shareholders' Meeting of CHC. Let's proceed according to the agenda.

Ⅲ. Matters for Report

1. 2024 business report: Please refer to Attachment 1
2. Audit committee's report on review of 2024 audited financial reports: Please refer to Attachment 2

3. To report the distribution of dividends and bonuses in cash of 2024
4. To report the distribution of the compensations for employees and remunerations for directors of 2024
5. To report the information of endorsements/guarantees in 2024: Please refer to Attachment 3
6. To report the status of the private placement of common shares resolved by 2024 Annual Shareholders' Meeting
7. To report the remunerations paid to directors in 2024: Please refer to Attachment 4
8. Amendment to "Code of Ethical Conduct": Please refer to Attachment 5
9. To report the purpose and related matters of the 5th domestic issuance of unsecured convertible corporate bonds: Please refer to Attachment 6

Ⅳ. Matters for Ratification

1. 2024 business report and financial statements
   (Proposed by Board of Directors)
   Explanation: (1). The Company's Parent Company Only Financial Statements and Consolidated Financial Statements for the Fiscal Year 2024 have been audited by independent auditors Yu-Fang, Yen, and Sheng-Wei, Teng, of PricewaterhouseCoopers (PwC) Taiwan, along with its 2024 Business Report, submitted to the audit committee for review and issuance of a written review report.
   (2). For "2024 Business Report", "2024 Audit Committee's Review Report", "Independent Auditors' Reports and Parent Company Only Financial Statements and Consolidated Financial Statements for the Fiscal Year 2024", please refer to Attachment 1, Attachment 2 and Attachment 7.
   (3). The proposal has been resolved by the Company's 9th audit committee's meeting of the 3rd term and by the 11th board meeting of the 7th term.
   (4). Please ratify it.
   Resolution: Voting result of the proposal is as follows: Total shares represented by the shareholders present at the time of voting are 102,930,281 shares. There are 93,187,205 votes in favor, 80,777 votes against, 0 vote invalid, 9,662,299 votes abstained. Votes in favor account for 90.53% of total representation at the time of voting, which means the proposal has been approved.

2. Proposal for 2024 earnings distribution

(Proposed by Board of Directors)

Explanation: (1). The Company's profit for the year 2024 is NT$168,384,912. After deducting NT$94,334 for retained earnings adjustments, setting aside a legal reserve for NT$16,829,058, appropriating a special reserve of NT$9,477,822 based on Article 41, paragraph 1 of "Securities and Exchange Act", and then adding unappropriated retained earnings at the beginning of the year 2024 for NT$273,650,732, the distributable unappropriated retained earnings for the year 2024 is NT$415,634,430. Proposal for earnings distribution is as follows:

CHC Healthcare Group

Table of 2024 Earnings Distribution

Item	Amount(NT$)	
	Subtotal	Total
Unappropriated retained earnings at the beginning of the year		273,650,732
Deduct: Retained earnings adjustments	(94,334)	
Add: Profit for the year	168,384,912	
Deduct: Legal reserve	(16,829,058)	
Deduct: Special reserve	(9,477,822)	
Subtotal		141,983,698
Distributable unappropriated retained earnings for the year		415,634,430
Distribution items:		
Cash dividends (NT$1.51 per share)		251,966,375
Unappropriated retained earnings at the end of the year		163,668,055

Chairman: Pei-Lin, Lee Managerial officer: Ming-Lun, Lee Accounting officer: Yi-Chun, Chen

(2). 2024 earnings distribution is first distributed from earnings in 2024 which is distributable.

(3). The proposal has been resolved by the Company's 9th audit committee's meeting of the 3rd term and by the 11th board meeting of the 7th term.

(4). Please ratify it.

Resolution: Voting result of the proposal is as follows: Total shares represented by the shareholders present at the time of voting are 102,930,281 shares. There are 93,305,536 votes in favor, 87,108 votes against, 0 vote invalid, 9,537,637 votes abstained. Votes in favor account for 90.64% of total representation at the time of voting, which means the proposal has been approved.

Ⅴ. Matters for Discussion

1. Amendment to "Articles of Incorporation"

(Proposed by Board of Directors)

Explanation: (1). The wording is revised as appropriate in accordance with the revision of relevant laws and regulations. For comparison table of revised articles, please refer to Attachment 8.

(2). The proposal has been resolved by the Company's 9th audit committee's meeting of the 3rd term and by the 11th board meeting of the 7th term.

(3). Please start discussion.

Resolution: Voting result of the proposal is as follows: Total shares represented by the shareholders present at the time of voting are 102,930,281 shares. There are 93,309,038 votes in favor, 81,940 votes against, 0 vote invalid, 9,539,303 votes abstained. Votes in favor account for 90.65% of total representation at the time of voting, which means the proposal has been approved.

2. To release the non-competition restrictions on directors

(Proposed by Board of Directors)

Explanation: (1). According to Article 209 of "Company Act": A director who does anything for himself or on behalf of another person that is within the scope of the company's business, shall explain to the meeting of shareholders the essential contents of such an act and secure its approval.

(2). It is proposed to the Meeting for approval to release the non-competition restrictions on directors due to the business operations and expansion needs of the Company. Please refer to Attachment 9 for details.

(3). The proposal has been resolved by the Company's 9th audit committee's meeting of the 3rd term and by the 11th board meeting of the 7th term.

(4). Please start discussion.

Resolution: Voting result of the proposal is as follows: Total shares represented by the shareholders present at the time of voting are 102,930,281 shares. There are 93,192,226 votes in favor, 175,373 votes against, 0 vote invalid, 9,562,682 votes abstained. Votes in favor account for 90.53% of total representation at the time of voting, which means the proposal has been approved.

3. To propose the issuance plan for a private placement of common shares

(Proposed by Board of Directors)

Explanation: (1). To enhance the relationship with strategic investors and consider the effectiveness of raising capital, the Company has proposed a private placement of common shares within the limit of 20,000 thousand shares and may be carried out in installments (no more than 3 times) within one year from the date resolved by the Meeting following Article 43-6 of "Securities and Exchange Act". Relevant information is as follows:

A. The basis for and reasonableness of pricing:

(a). The price per share set for privately placed common shares may not be lower than 80% of the reference price. The reference price shall be the higher of the following two calculations:

(i). The simple average closing price of the common shares for either the 1, 3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction.

(ii). The simple average closing price of the common shares for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction.

(b). It is proposed to the Meeting to authorize the Board of Directors to determine the actual price determination date and issuance price in accordance with the status of selecting the specific persons and the market situation, also the price can't be lower than the percentage for the private placement pricing set by the Meeting.

(c). It is believed to be reasonable due to the basis for the method by which the price was set and terms above are all complied with relevant laws and regulations and in line with market situation.

B. The method, objectives, necessity and anticipated benefits for selecting the specific persons:

(a). The method and objectives for selecting the placees: To enhance the relationship with strategic investors, the Company plans to select the specific persons in accordance with Article 43-6 of "Securities and Exchange Act".

(b). The necessity and anticipated benefits: The Company proposed to engage with strategic investors through private placement to raise capital for the Company's long-term operating plan and future business development. It is expected that the private placement will strengthen future competitiveness, improve financial structure, enrich working capital and have advantage on the Company's long-term development. Cooperation with strategic investors may lead to broader business territory, which also has positive influence on shareholders' equity.

C. The reasons for the necessity for conducting the private placement:

(a). The reasons for not using a public offering: The regulation of a three-year non-trading period will help assure the long-term relationship between the strategic investors and the Company through private placement.

(b). The limit on the private placement: Within the limit of 20,000 thousand shares

(c). The use of the capital raised by installments and the anticipated benefits: The capital raised by installments through the private placement will be used to enrich working capital and for future development needs. It is expected to strengthen financial structure, replenish working capital and improve competitiveness of the Company.

D. The Company has not experienced any significant change in managerial control due to the introduction of a strategic investor through private placement or other factors in the previous year.

(2). The new private placement shares shall have the same rights and obligations as holders of common shares of the Company except for the transfer limitation of privately placed securities within three years of the delivery date stated in Article 43-8 of "Securities and Exchange Act". It is proposed to the Meeting to authorize the Board of Directors to apply to the competent authority for retroactive handling of public issuance procedures for the private placement shares after three full years since the delivery date based on "Securities and Exchange Act" and relevant rules.

(3). It is proposed to the Meeting to authorize the Board of Directors to make amendment and supplement to the issuance price, terms and conditions, particulars of the plan and the actual status and other relevant matters related to the private placement if there occurs any update of R.O.C. laws or regulations, request by the authority, change of the market conditions or due to any subjective and objective factors.

(4). It is proposed to the Meeting to authorize the Chairman to represent the Company to negotiate and sign any document and contract related to the private placement plan, also to handle the relevant issuance matters on behalf of the Company.

(5). The proposal has been resolved by the Company's 9th audit committee's meeting of the 3rd term and by the 11th board meeting of the 7th term.

(6). Please start discussion.

Resolution: Voting result of the proposal is as follows: Total shares represented by the shareholders present at the time of voting are 102,930,281 shares. There are 90,938,574 votes in favor, 2,446,620 votes against, 0 vote invalid, 9,545,087 votes abstained. Votes in favor account for 88.34% of total representation at the time of voting, which means the proposal has been approved.

Ⅵ. Extemporary Motions: None

(No question asked by the shareholders at the Meeting.)

Ⅶ. Meeting Adjourned: At 09:26 a.m.

【Attachment 1】

CHC Healthcare Group
2024 Business Report

Dear Shareholders:

Thank you for your support and advice to CHC Healthcare Group, which has enabled the Group to maintain stable development in a highly competitive environment. In 2024, however, due to various external challenges, the Group's operational performance fell short of expectations. CHC extends its deepest apologies to all shareholders. Nevertheless, the Group firmly believes that with the continued support of shareholders and the tireless efforts of all colleagues, it will be able to regain growth momentum and strive to maximize the interests of both shareholders and employees.

1. 2024 business operation results

(1). 2024 business plan implementation

The consolidated operating revenue for 2024 was NT$3,600,574 thousand, representing a decrease compared to NT$3,877,137 thousand in 2023, mainly due to a decline in instrument sales volume in 2024. The profit for the year 2024 was NT$182,577 thousand, down from NT$425,238 thousand in 2023, primarily due to the decrease in operating revenue. The consolidated operating results for the year 2024 are as follows:

Unit: NT$ thousand

Item	2024
Operating revenue	3,600,574
Gross profit	759,125
Operating expenses	520,415
Operating profit	238,710
Profit before income tax	223,007
Profit for the year	182,577

(2). Budget execution

The Group did not disclose the 2024 financial forecast, and therefore is not required to disclose the budget execution status.

(3). Revenue/expenditure and profitability

Item		2024	2023
Financial structure and solvency	Debt ratio (%)	53.06%	50.23%
	Current ratio (%)	136.47%	303.76%
Profitability	Return on total assets (%)	2.08%	3.96%
	Return on equity (%)	2.72%	6.45%
	Net profit margin (%)	5.07%	10.97%
	Basic earnings per share (NT$)	NT$1.01	NT$2.55

(4). R&D status

The Group is not in the manufacturing industry and therefore does not have a dedicated R&D department, nor did it incur any R&D expenses in 2024.

2. 2025 business plan outline

(1). Product development strategy

The Group has long dedicated to introducing advanced medical equipment and technologies to enhance the quality of medical treatment domestically. In recent years, it has actively promoted precision medicine by introducing systems such as proton therapy and MRI linear accelerators, aiming to eliminate tumors while maximizing the protection of patients' normal tissues.

In addition to maintaining stable partnerships with leading international medical equipment manufacturers, the Group will actively seek out new products through various exhibitions to further expand its product portfolio in the future. By leveraging its existing medical sales channels, the Group aims to boost revenue and create a three-win situation for the Group, patients, and medical institutions.

(2). Medical management service guideline

The Group has developed a full range of medical management services from medical site planning, design and construction, medical equipment installation and testing, division management and operation consulting, medical technician training, to equipment maintenance and subsequent upgrade services.

The key for medical management service to be rooted in Taiwan and to be extended to the overseas market is that the Group has a professional technical team certified by the manufacturers. Instant and high-quality technical support together with flexible and innovative cooperation models helps the Group to form differentiated competitiveness, thereby strengthening the Group's relationship with both customers and suppliers. In the future, the Group will continue to train the technical team to extend the depth and breadth of medical management services to facilitate the business expansion.

(3). Health industry layout

As Taiwan transitions from an aged society to a super-aged society, the growing emphasis on personal health among Taiwanese people has been noted. CHC has expanded its business territories from B2B to B2C step by step, aiming to improve the overall health and well-being of human beings.

Currently, the Group has successfully entered the chain community pharmacy market and is going to continue expanding the number of cooperative channels, enhancing the scale and level of existing physical and online channels to meet the personal and family health management needs of consumers. Moreover, in response to the aging trend, the Group has cooperated with Sakurajyuji Group from Japan to engage in Taiwan's elderly care market, focusing on continuing care and preventive medicine, hoping to postpone disability and dementia through health promotion and improve the quality and dignity of life for elderly in Taiwan.

(4). Irradiation business development

CHC actively monitors external environmental changes and market trends and has diversified into various fields starting from the medical industry in recent years, considering the international environment safety and health trends as well as domestic industrial demands, intending to develop the irradiation business.

The Group has exclusively introduced the Belgian IBA irradiation system, which aligns with the principles of sustainable use. This system generates high-energy photon and electron beams, offering a safer, more efficient, and residue-free sterilization method for healthcare, food, and other livelihood-related industries, effectively replacing traditional chemical gas sterilization. It also meets the testing requirements of industries such as aerospace and low-earth orbit satellites and is applicable in semiconductor and composite material processing, delivering innovative solutions across various sectors.

Chairman: Pei-Lin, Lee Managerial officer: Ming-Lun, Lee Accounting officer: Yi-Chun, Chen

【Attachment 2】

CHC Healthcare Group
2024 Audit Committee's Review Report

TO: 2025 Annual Shareholders' Meeting of CHC Healthcare Group

The Company's Board of Directors has submitted the Consolidated Financial Statements and Parent Company Only Financial Statements for the Fiscal Year 2024, which have been audited by independent auditors Yu-Fang, Yen, and Sheng-Wei, Teng, of PricewaterhouseCoopers (PwC) Taiwan. Independent Auditors' Reports stated that, in their opinion, the financial position, operating results, and cash flows are fairly presented. Along with the 2024 business report and proposal for 2024 earnings distribution, the audit committee has reviewed and found no discrepancies. Therefore, under Article 14 of the Securities Exchange Act and Article 219 of the Company Act, we hereby report the above for your reference and verification.

CHC Healthcare Group

By
Ming-Liang, Kao
Convener of audit committee

March 12, 2025

【Attachment 3】

CHC Healthcare Group

Information of Endorsements/Guarantees in 2024

The Company's information of endorsements/guarantees by December 31, 2024:

1. Counterparty: Four 100% owned subsidiaries
2. Total amount of endorsements/guarantees: NT$2,989,000 thousand
3. Purpose of endorsements/guarantees: For subsidiaries' financing needs
4. According to the net worth on December 31, 2024, the ceiling on total amount of the Company's endorsements/guarantees is NT$18,909,814 thousand and the ceiling on amount of the Company's endorsements/guarantees to any individual entity is NT$12,606,542 thousand. All endorsements/guarantees the Company made are pursuant to "Procedures for Endorsement & Guarantee" and there is no circumstance that the amount exceeds the ceiling.

Item	Counterparty	Amount (NT$ thousand)
1	Chiu Ho Medical System Co., Ltd.	850,000
2	Tomorrow Medical System Co., Ltd.	1,288,000
3	Chiu Ho Scientific Co., Ltd.	80,000
4	Shin-Ho Biotech Co., Ltd.	771,000
Total amount		2,989,000

5. Subsidiaries' information of endorsements/guarantees by December 31, 2024:

Item	Provider	Counterparty	Amount (NT$ thousand)
1	Chiu Ho Medical System Co., Ltd.	CHC Healthcare Group	1,106,687
2	Chiu Ho Medical System Co., Ltd.	Tomorrow Medical System Co., Ltd.	621,674
Total amount			1,728,361

【Attachment 4】

CHC Healthcare Group

Remunerations Paid to Directors in 2024

Unit: NT$ thousand, thousand shares, %

Title				Chairman	Vice chairman	Director	Director	Independent director	Independent director	Independent director
Name				Pei-Lin, Lee	Tien-Ying, Lee	Chun-Shung, Huang	Yung-Shun, Chuang	Geng-Wang, Liaw	Chi, Chih	Ming-Liang, Kao
Director's remuneration	Base remuneration (A)	From CHC		0	0	0	0	0	0	0
		From all consolidated entities		0	0	0	0	0	0	0
	Severance pay and pension (B)	From CHC		0	0	0	0	0	0	0
		From all consolidated entities		0	0	0	0	0	0	0
	Remuneration for director (C)	From CHC		800	800	800	800	800	800	800
		From all consolidated entities		800	800	800	800	800	800	800
	Business execution expense (D)	From CHC		32	40	40	40	169	169	169
		From all consolidated entities		32	40	40	40	169	169	169
Total (A+B+C+D) & ratio of total to net income (%)		From CHC		832 0.48%	840 0.50%	840 0.50%	840 0.50%	969 0.58%	969 0.58%	969 0.58%
		From all consolidated entities		832 0.48%	840 0.50%	840 0.50%	840 0.50%	969 0.58%	969 0.58%	969 0.58%
Compensation received as employee	Salary, bonus, and allowance (E)	From CHC		10,661	9,121	0	0	0	0	0
		From all consolidated entities		10,661	9,121	0	0	0	0	0
	Severance pay and pension (F)	From CHC		0	0	0	0	0	0	0
		From all consolidated entities		0	0	0	0	0	0	0
	Compensation for employee (G)	From CHC	Cash	0	0	0	0	0	0	0
			Share	0	0	0	0	0	0	0
		From all consolidated entities	Cash	0	0	0	0	0	0	0
			Share	0	0	0	0	0	0	0
Total (A+B+C+D+E+F+G) & ratio of total to net income (%)		From CHC		11,493 6.82%	9,961 5.91%	840 0.50%	840 0.50%	969 0.58%	969 0.58%	969 0.58%
		From all consolidated entities		11,493 6.82%	9,961 5.91%	840 0.50%	840 0.50%	969 0.58%	969 0.58%	969 0.58%
Compensation from other non-consolidated entities invested by CHC				None	None	None	None	None	None	None

1. Please state the payment policy, system, standard, and structure of the independent directors' remuneration, and describe the amount paid in linkage to responsibilities, risks, time spent, and related factors: The Company has taken out liability insurance for all independent directors and has given a fixed amount of remuneration based on the actual participation of each independent director in the functional committees and the Board of Directors. Total remunerations paid to directors will be decided according to the Company's annual operating results and reported to the shareholders' meeting. Benchmark for the remuneration of individual directors will be determined by the results of the internal evaluation of the Board of Directors, self-evaluation by individual board members, evaluation by appointed external professional institutions, or other appropriate methods.
2. Except as disclosed in the above table, remunerations received by the directors due to providing services to any of the entities listed in the consolidated financial statement (e.g. act as a consultant in a non-employee capacity for CHC, entities listed in the consolidated financial statement, investee enterprises, etc.) in the most recent year: None

【Attachment 5】

CHC Healthcare Group

Comparison Table of Revised Articles of "Code of Ethical Conduct"

Article before revision	Article after revision	Explanation
Article 2 Content of the Code 1. Preventing Conflicts of Interest: Conflicts of interest occur when personal interest intervenes or is likely to intervene in the overall interest of the Company, as for example when a director or managerial officer of the Company is unable to perform their duties in an objective and efficient manner, or when a person in such a position takes advantage of their position in the Company to obtain improper benefits for either themselves or their spouse, parents, children, or relatives within the second degree of kinship. The Company shall pay special attention to loans of funds, provisions of guarantees, and major asset transactions or the purchase (or sale) of goods involving the affiliated enterprise related to the aforementioned personnel. If the transactions mentioned above happened, in order to prevent the Company from conflicts of interest, related personnel shall voluntarily explain if there is any potential conflicts of interest between themselves and the Company and shall follow the regulation of the Company to deal with it. (Paragraphs omitted.) 8. Disciplinary Measures: When a director or managerial officer violates the Code of Ethical Conduct, the Company shall handle the matter in accordance with the law and the regulations of the Company, and shall without delay disclose on the Market Observation Post System (MOPS) the date of the violation by the violator, reasons for the violation, the provisions of the code violated, and the disciplinary actions taken if the violation is serious.	Article 2 Content of the Code 1. Preventing Conflicts of Interest: Conflicts of interest occur when personal interests interfere or are likely to interfere with ~~intervenes or is likely to intervene in~~ the overall interests of the Company, as for example when a director or managerial officer ~~of the Company~~ is unable to perform their duties ~~in an~~ objectively and efficiently ~~manner~~, or when ~~a person in such a position takes advantage of~~ their position in the Company enables them, their spouse, or relatives within the second degree of kinship to obtain improper benefits ~~for either themselves or their spouse, parents, children, or relatives within the second degree of kinship~~. The Company shall pay special attention to transactions involving loans of funds, provisions of guarantees, major asset transactions, or the purchase and sale of goods with affiliated enterprises related to the aforementioned personnel. The Company shall establish policies to prevent conflicts of interest and provide appropriate channels for directors or managerial officers to proactively disclose any potential conflicts of interest with the Company. ~~The Company shall pay special attention to loans of funds, provisions of guarantees, and major asset transactions or the purchase (or sale) of goods involving the affiliated enterprise related to the aforementioned personnel. If the transactions mentioned above happened, in order to prevent the Company from conflicts of interest, related personnel shall voluntarily explain if there is any potential conflicts of interest between themselves and the Company and shall follow the regulation of the Company to deal with it.~~ (Paragraphs omitted.) 8. Disciplinary Measures: When a director or managerial officer violates the Code of Ethical Conduct,	Revise wording as appropriate in accordance with the revision to the templates announced by the Taiwan Stock Exchange

<table>
<tr><th>Article before revision</th><th>Article after revision</th><th>Explanation</th></tr>
<tr><td></td><td>the Company shall handle the matter in accordance with the disciplinary measures established in the code of ethical conduct ~~law and the regulations of the Company,~~ and shall without delay disclose on the Market Observation Post System ~~(MOPS)~~ the date of the violation ~~by the violator~~, reasons for the violation, the provisions of the code violated, and the disciplinary actions taken ~~if the violation is serious~~. The Company shall also establish an appeal system to provide remedies for individuals who violate the code of ethical conduct.</td><td></td></tr>
<tr><td>
<table>
<tr><th>Version</th><th>Date of Implementation /Amendment</th><th>Type of Approval</th></tr>
<tr><td>1</td><td>2014/03/27</td><td>Approved by Board of Directors</td></tr>
<tr><td>2</td><td>2015/03/23</td><td>Approved by Board of Directors</td></tr>
<tr><td>3</td><td>2017/08/10</td><td>Approved by Board of Directors</td></tr>
</table>
</td><td>
<table>
<tr><th>Version</th><th>Date of Implementation /Amendment</th><th>Type of Approval</th></tr>
<tr><td>1</td><td>2014/03/27</td><td>Approved by Board of Directors</td></tr>
<tr><td>2</td><td>2015/03/23</td><td>Approved by Board of Directors</td></tr>
<tr><td>3</td><td>2017/08/10</td><td>Approved by Board of Directors</td></tr>
<tr><td>4</td><td>2025/03/12</td><td>Approved by Board of Directors</td></tr>
</table>
</td><td>Add amending date.</td></tr>
</table>

【Attachment 6】

CHC Healthcare Group

Report on the Purpose and Related Matters of the 5th Domestic Issuance of Unsecured Convertible Corporate Bonds

For the purpose of repaying the Company's 4th domestic issuance of secured convertible corporate bonds (41644) and bank loans, the Company, following resolutions by the audit committee and the Board of Directors on December 2, 2024, obtained approval from the Financial Supervisory Commission R.O.C. (Taiwan) via Letter No. 1130367071 dated December 30, 2024. The Company will issue the 5th domestic unsecured convertible corporate bonds, totaling 15,000 units, each with a face value of NT$ 100,000. The total issuance amount of face value will be up to NT$1.5 billion, with an issuance period of five years. The bonds will bear a zero percent coupon rate and will be issued at 100% to 103% of face value. The maximum fundraising amount is NT$1,545,000,000.

The Company originally planned to complete the fundraising and issuance of the 5th domestic unsecured convertible corporate bonds in the first quarter of 2025. However, due to fluctuations in the domestic capital market, in order to avoid abrupt pricing that may impair shareholders' interests, and taking into account investors' willingness to subscribe and the feasibility of fundraising, the Company applied to the Financial Supervisory Commission for an extension of the fundraising period.

The application for the extension has been approved and acknowledged by the Financial Supervisory Commission R.O.C. (Taiwan) via Letter No. 1140337237 dated March 21, 2025. The fundraising period has been extended, with the issuance to be completed by June 29, 2025. The funds raised are scheduled to be utilized in the second and third quarters of 2025.

【Attachment 7】

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of CHC Healthcare Group

Opinion

We have audited the accompanying parent company only balance sheets of CHC Healthcare Group (the "Company") as at December 31, 2024 and 2023, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2024 and 2023, and its financial performance and its cash flows for the years then ended, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the *Auditors' responsibilities for the audit of the parent company only financial statements* section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company's 2024 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Company's 2024 parent company only financial statements are stated as follows:

Assessment of investments accounted for using equity method

Refer to Note 4(9) for accounting policy on investments accounted for using equity method, Note 5(2) for uncertainty of accounting estimates and assumptions in relation to impairment assessment of investments accounted for using equity method, and Note 6(4) for details of investments accounted for using equity method.

Impairment assessment of Chiu Ho Medical System Co., Ltd. and Treasure of Health Co., Ltd., the Company's subsidiaries

As of December 31, 2024, the Company's subsidiaries, Treasure of Health Co., Ltd. (Treasure of Health), and Chiu Ho Medical System Co., Ltd. and its subsidiaries ("Chiu Ho Medical Group"), recognised investments accounted for using equity method amounting to NT$415,228 thousand and NT$4,835,997 thousand, respectively, and investment income amounting to NT$10,170 thousand and NT$119,771 thousand for the years then ended, respectively. Because the investments in Treasure of Health and Chiu Ho Medical Group accounted for using equity method constituted 57% of the Company's total assets as of December 31, 2024, and investment income constituted 76% of the Company's profit before tax for the year ended December 31, 2024, which are significant to the Company's financial statements, we identified the assessment of investments accounted for using equity method as a key audit matter as well as the key audit matters, impairment assessment of goodwill and property, plant and equipment, included in Chiu Ho Medical Group's financial statements. The key audit matters in relation to Treasure of Health and Chiu Ho Medical Group's financial statements for the year ended December 31, 2024 are stated as follows:

Impairment assessment of goodwill

Description

As of December 31, 2024, after identifying the smallest cash generating unit which can generate independent cash flows, Treasure of Heath and Chiu Ho Medical Group used the recoverable amount of each cash generating unit to assess whether goodwill arising from business combination may be impaired. Since the assumptions used by management to assess whether goodwill is impaired involve subjective judgement and have high uncertainty, we considered the impairment assessment of goodwill as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

A. Obtained an understanding on how management identifies the objective evidence of goodwill impairment, taking into account certain factors in a consistent manner and ascertained whether the management uses reliable information.

B. Obtained the report on the valuation of the subsidiary issued by an expert appointed by the management and performed the following:

   (1) Assessed the expert's independence, objectiveness and competence by reviewing the expert's qualification.

   (2) Assessed whether the valuation model is reasonable based on our knowledge of Treasure of Health and Chiu Ho Medical Group's businesses and industry.

   (3) Confirmed whether the expert uses the same future cash flows relative to the budget for the future years provided by the management.

   (4) Checked whether the comparable assets adopted in the appraisal report are consistent with the actual operations.

   (5) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Impairment assessment of property, plant and equipment

Description

Some of Chiu Ho Medical Group's leasing businesses were not as profitable as expected due to fierce competition in the healthcare industry. Chiu Ho Medical Group assesses the impairment based on the estimated recoverable amounts of leased assets (shown as property, plant and equipment) where there is an indication that they are impaired. Given that the calculation of recoverable amounts requires significant accounting estimates relying on subjective judgement and a high degree of uncertainty, we considered the impairment assessment of leased assets as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

A. Obtained an understanding on how management identifies the objective evidence of impairment, taking into account certain factors in a consistent manner and ascertained whether

the management uses reliable information.

B. Acquired the asset appraisal report issued by an expert appointed by the management and performed the following:

(1) Assessed the independence, objectiveness and competence by reviewing the expert's qualification.

(2) Assessed whether the valuation method is widely adopted and appropriate based on our knowledge of Chiu Ho Medical Group's businesses and industry.

(3) Confirmed whether the replacement cost, comparative objects and the assets' use indicated on the appraisal report are consistent with the actual operations.

(4) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Responsibilities of management and those charged with governance for the parent company only financial statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal controls as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' responsibilities for the audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit conducted in accordance with the Standards of Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud

or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

A. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
B. Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal controls.
C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
D. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
E. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
F. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For and on behalf of PricewaterhouseCoopers, Taiwan
March 12, 2025

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Assets	Notes	December 31, 2024 Amount	%	December 31, 2023 Amount	%
	Current assets					
1100	Cash and cash equivalents	6(1)	$ 156,244	2	$ 217,382	2
1110	Financial assets at fair value through profit or loss - current	6(2)	49,669	-	69,380	1
1200	Other receivables		-	-	300	-
1210	Other receivables due from related parties	7	436,112	5	161,548	2
1220	Current tax assets		102	-	-	-
1410	Prepayments		5,706	-	6,329	-
11XX	**Total current assets**		647,833	7	454,939	5
	Non-current assets					
1510	Financial assets at fair value through profit or loss - non-current	6(2)	9,081	-	7,829	-
1517	Financial assets at fair value through other comprehensive income - non-current	6(3)	12,724	-	10,159	-
1550	Investments accounted for using equity method	6(4)	8,508,424	92	8,718,787	94
1600	Property, plant and equipment		608	-	628	-
1755	Right-of-use assets	6(5)	23,516	-	30,399	-
1840	Deferred tax assets	6(20)	58,616	1	58,625	1
1990	Other non-current assets		572	-	269	-
15XX	**Total non-current assets**		8,613,541	93	8,826,696	95
1XXX	**Total assets**		$ 9,261,374	100	$ 9,281,635	100

(Continued)

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Liabilities and Equity	Notes	December 31, 2024 Amount	%	December 31, 2023 Amount	%
	Current liabilities					
2100	Short-term borrowings	6(6)	$ 250,000	3	$ 100,000	1
2150	Notes payable		135	-	135	-
2200	Other payables		22,097	-	21,607	-
2230	Current tax liabilities		1,774	-	131	-
2280	Lease liabilities - current	7	6,828	-	6,702	-
2320	Long-term liabilities, current portion	6(7)	1,306,507	14	-	-
2399	Other current liabilities		997	-	986	-
21XX	**Total current liabilities**		1,588,338	17	129,561	1
	Non-current liabilities					
2530	Bonds payable	6(7)	-	-	1,317,066	14
2540	Long-term borrowings	6(8)	1,352,000	15	1,352,000	15
2570	Deferred tax liabilities	6(20)	734	-	734	-
2580	Lease liabilities - non-current	7	17,031	-	23,859	-
25XX	**Total non-current liabilities**		1,369,765	15	2,693,659	29
2XXX	**Total liabilities**		2,958,103	32	2,823,220	30
	Equity					
	Share capital	6(7)(10)(11)				
3110	Common stock		1,668,651	18	1,664,194	18
	Capital surplus	6(7)(10)(12)				
3200	Capital surplus		3,732,745	40	3,716,656	40
	Retained earnings	6(13)				
3310	Legal reserve		469,411	5	427,524	5
3320	Special reserve		385,664	4	387,424	4
3350	Unappropriated retained earnings		441,941	5	648,281	7
	Other equity	6(3)				
3400	Other equity		(395,141)	(4)	(385,664)	(4)
3XXX	**Total equity**		6,303,271	68	6,458,415	70
	Significant contingent liabilities and unrecognised contract commitments	9				
	Significant events after the balance sheet date	11				
3X2X	**Total liabilities and equity**		$ 9,261,374	100	$ 9,281,635	100

The accompanying notes are an integral part of these parent company only financial statements.

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT FOR EARNINGS PER SHARE AMOUNTS)

	Items	Notes	2024 Amount	2024 %	2023 Amount	2023 %
4000	**Operating revenue**	6(14) and 7	$ 334,154	100	$ 564,220	100
5000	**Operating costs**	6(5)(9)(10)(19)	(122,032)	(37)	(112,820)	(20)
5900	**Gross profit**		212,122	63	451,400	80
	Non-operating income and expenses					
7100	Interest income	6(15) and 7	9,037	3	3,365	1
7010	Other income	6(16)	339	-	1,553	-
7020	Other gains and losses	6(2)(17)	4,032	1	12,994	2
7050	Finance costs	6(18)	(55,159)	(16)	(49,811)	(9)
7000	**Total non-operating income and expenses**		(41,751)	(12)	(31,899)	(6)
7900	**Profit before income tax**		170,371	51	419,501	74
7950	Income tax expense	6(20)	(1,987)	-	(635)	-
8200	**Profit for the year**		$ 168,384	51	$ 418,866	74
	Other comprehensive income					
	Components of other comprehensive income that will not be reclassified to profit or loss					
8316	Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(3)	$ 2,565	1	($ 378)	-
8330	Share of other comprehensive income of associates and joint ventures accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss		-	-	7,759	2
	Components of other comprehensive income that will be reclassified to profit or loss					
8361	Financial statements translation differences of foreign operations		(14,608)	4	(5,650)	(1)
8380	Share of other comprehensive income (loss) of associates and joint ventures accounted for using equity method, components of other comprehensive income that will be reclassified to profit or loss		(5)	-	28	-
8300	**Other comprehensive income for the year**		$ 17,168	5	$ 1,759	1
8500	**Total comprehensive income for the year**		$ 185,552	56	$ 420,625	75
	Earnings per share (in dollars)					
9750	Basic earnings per share	6(21)	$	1.01	$	2.55
9850	Diluted earnings per share	6(21)	$	0.98	$	2.26

The accompanying notes are an integral part of these parent company only financial statements.

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	Capital Reserves			Retained Earnings			Other Equity Interest			
		Common stock	Capital surplus	Employee stock warrants	Others	Legal reserve	Special reserve	Unappropriated retained earnings	Financial statements translation differences of foreign operations	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Others	Total equity
2023												
Balance at January 1, 2023		$ 1,615,531	$ 3,476,727	$ 8,551	$ 59,145	$ 391,867	$ 395,708	$ 581,510	($ 35,386)	($ 352,037)	$ -	$ 6,141,616
Profit for the year		-	-	-	-	-	-	418,866	-	-	-	418,866
Other comprehensive income (loss)		-	-	-	-	-	-	-	(5,622)	7,381	-	1,759
Total comprehensive income (loss)		-	-	-	-	-	-	418,866	(5,622)	7,381	-	420,625
Appropriations of 2022 earnings	6(13)											
Legal reserve		-	-	-	-	35,657	-	(35,657)	-	-	-	-
Cash dividends		-	-	-	-	-	-	(324,722)	-	-	-	(324,722)
Reversal of special reserve		-	-	-	-	-	(8,284)	8,284	-	-	-	-
Conversion of convertible bonds	6(7)(11)	41,933	163,705	-	(3,396)	-	-	-	-	-	-	202,242
Exercise of employee stock options	6(10)(11)	6,730	18,636	(6,998)	-	-	-	-	-	-	-	18,368
Compensation cost of employee stock options	6(10)	-	-	99	-	-	-	-	-	-	-	99
Compensation cost of employee stock options of subsidiaries		-	-	187	-	-	-	-	-	-	-	187
Employee stock options expired		-	-	(108)	108	-	-	-	-	-	-	-
Balance at December 31, 2023		$ 1,664,194	$ 3,659,068	$ 1,731	$ 55,857	$ 427,524	$ 387,424	$ 648,281	($ 41,008)	($ 344,656)	$ -	$ 6,458,415
2024												
Balance at January 1, 2024		$ 1,664,194	$ 3,659,068	$ 1,731	$ 55,857	$ 427,524	$ 387,424	$ 648,281	($ 41,008)	($ 344,656)	$ -	$ 6,458,415
Profit for the year		-	-	-	-	-	-	168,384	-	-	-	168,384
Other comprehensive income		-	-	-	-	-	-	-	14,603	2,565	-	17,168
Total comprehensive income		-	-	-	-	-	-	168,384	14,603	2,565	-	185,552
Appropriations of 2023 earnings	6(13)											
Legal reserve		-	-	-	-	41,887	-	(41,887)	-	-	-	-
Cash dividends		-	-	-	-	-	-	(334,502)	-	-	-	(334,502)
Reversal of special reserve		-	-	-	-	-	(1,760)	1,760	-	-	-	-
Conversion of convertible bonds	6(7)(11)	4,157	15,943	-	(330)	-	-	-	-	-	-	19,770
Exercise of employee stock options	6(10)(11)	300	803	(327)	-	-	-	-	-	-	-	776
Compensation cost of employee stock options of subsidiaries		-	-	-	1,948	-	-	-	-	-	-	1,948
Disposal of subsidiaries		-	-	-	(1,948)	-	-	(95)	-	-	-	(2,043)
Redemption liabilities of subsidiaries		-	-	-	-	-	-	-	-	-	(26,645)	(26,645)
Balance at December 31, 2024		$ 1,668,651	$ 3,675,814	$ 1,404	$ 55,527	$ 469,411	$ 385,664	$ 441,941	($ 26,405)	($ 342,091)	($ 26,645)	$ 6,303,271

The accompanying notes are an integral part of these parent company only financial statements.

CHC HEALTHCARE GROUP
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		$ 170,371	$ 419,501
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation charge	6(19)	7,206	7,281
Amortisation charge	6(19)	197	162
Net gain on financial assets or liabilities at fair value through profit or loss	6(2)(17)	(4,030)	(13,089)
Interest expense	6(18)	45,924	39,937
Interest income	6(15)	(9,037)	(3,365)
Dividend income	6(16)	(330)	(1,052)
Compensation cost of employee stock options	6(10)(19)	-	99
Share of profit of associates and joint ventures accounted for using equity method	6(14)	(194,764)	(423,600)
Amortisation of discount on bonds payable	6(18)	9,235	9,874
Changes in operating assets and liabilities			
Changes in operating assets			
Financial assets at fair value through profit or loss		22,465	(16,499)
Other receivables due from related parties		-	369
Prepayments		623	839
Changes in operating liabilities			
Other payables		456	(3,136)
Other current liabilities		11	59
Cash inflow generated from operations		48,327	17,380
Interest received during the year		4,473	3,441
Dividends received during the year		328,867	217,538
Interest paid during the year		(45,826)	(39,925)
Income tax paid		(437)	(502)
Net cash flows from operating activities		335,404	197,932
CASH FLOWS FROM INVESTING ACTIVITIES			
(Increase) decrease in other receivables due from related parties	7	(270,000)	10,000
Acquisition of investments accounted for using equity method	6(4) and 7	(71,247)	-
Proceeds from capital reduction of investments accounted for using equity method	7	136,000	140,000
Acquisition of property, plant and equipment		(367)	(139)
Increase in other non-current assets		(500)	-
Net cash flows from investing activities		(206,114)	149,861
CASH FLOWS FROM FINANCING ACTIVITIES			
Increase in short-term loans	6(22)	1,550,000	890,000
Decrease in short-term loans	6(22)	(1,400,000)	(890,000)
Payments of lease liabilities	6(22)	(6,702)	(6,844)
Proceeds from long-term debt	6(22)	-	200,000
Repayments of long-term debt	6(22)	-	(200,000)
Exercise of employee stock options		776	18,368
Payment of cash dividends	6(13)	(334,502)	(324,722)
Net cash flows used in financing activities		(190,428)	(313,198)
(Decrease) increase in cash and cash equivalents		(61,138)	34,595
Cash and cash equivalents at beginning of year		217,382	182,787
Cash and cash equivalents at end of year		$ 156,244	$ 217,382

The accompanying notes are an integral part of these parent company only financial statements.

REPRESENTATION LETTER

The entities that are required to be included in the combined financial statements of CHC Healthcare Group as of and for the year ended December 31, 2024, under the Criteria Governing the Preparation of Affiliation Reports, Consolidated Business Reports and Consolidated Financial Statements of Affiliated Enterprises are the same as those included in the consolidated financial statements prepared in conformity with the International Financial Reporting Standard 10, “Consolidated Financial Statements.” In addition, the information required to be disclosed in the combined financial statements is included in the consolidated financial statements. Consequently, CHC Healthcare Group and Subsidiaries do not prepare a separate set of combined financial statements.

Very truly yours,

CHC HEALTHCARE GROUP

By

Pei-Lin Lee
Chairman

March 12, 2025

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of CHC Healthcare Group

Opinion

We have audited the accompanying consolidated balance sheets of CHC Healthcare Group and subsidiaries (the "Group") as at December 31, 2024 and 2023, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2024 and 2023, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the *Auditors' responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group's 2024 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion

thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Group's 2024 consolidated financial statements are stated as follows:

Impairment assessment of goodwill

Description

As of December 31, 2024, the Group generated goodwill of NT$150,617 thousand and NT$202,834 thousand as a result of the merger with Shih-Lu Co., Ltd. and with Treasure of Health Co., Ltd., respectively.

After identifying the smallest cash generating unit which can generate independent cash flows, the Group used the recoverable amount of each cash generating unit to assess whether goodwill may be impaired. Since the assumptions used by management to assess whether goodwill is impaired involve subjective judgment and have high uncertainty, we considered the impairment assessment of goodwill as a key audit matter.

Refer to Note 4(20) for the accounting policy on goodwill impairment, Note 5(2) for uncertainty of accounting estimates and assumptions in relation to goodwill impairment and Note 6(13) for related details.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

A. Obtained an understanding on how management identifies the objective evidence of goodwill impairment, taking into account certain factors in a consistent manner and ascertained whether the management uses reliable information.

B. Obtained the report on the valuation of the subsidiary issued by an expert appointed by the management and performed the following:

(1) Assessed the expert's independence, objectiveness and competence by reviewing the expert's qualification.

(2) Assessed whether the valuation model is reasonable based on our knowledge of the Group's businesses and industry.

(3) Confirmed whether the expert uses the same future cash flows relative to the budget for the

future years provided by the management.

(4) Checked whether the comparable assets adopted in appraisal report are consistent with the actual operations.

(5) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Impairment assessment of property, plant and equipment

Description

Some of the Group's leasing businesses were not as profitable as expected due to fierce competition in the healthcare industry. The Group assesses the impairment based on the estimated recoverable amounts of leasing assets (shown as property, plant and equipment) where there is an indication that they are impaired. Given that the calculation of recoverable amounts requires significant accounting estimates relying on subjective judgment and uncertainty, we considered the impairment assessment of leasehold assets as a key audit matter.

Refer to Note 4(20) for the accounting policy on asset impairment and Note 5(2) for accounting estimates and assumption uncertainty of asset impairment.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

A. Obtained an understanding on how management identifies the objective evidence of impairment, taking into account certain factors in a consistent manner and ascertained whether the management uses reliable information.

B. Acquired the asset appraisal report issued by an expert appointed by the management and performed the following:

(1) Assessed the independence, objectiveness and competence by reviewing the expert's qualification.

(2) Assessed whether the valuation method is widely adopted and appropriate based on our knowledge of the Group's businesses and industry.

(3) Confirmed whether the replacement cost, comparative objects and the assets' use indicated on the appraisal report are consistent with the actual operations.

(4) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Other matter – Parent company only financial reports

We have audited and expressed an unmodified opinion on the parent company only financial statements of CHC Healthcare Group as at and for the years ended December 31, 2024 and 2023.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial

statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

A. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
B. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal controls.
C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
D. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
E. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
F. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For and on behalf of PricewaterhouseCoopers, Taiwan
March 12, 2025

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Assets	Notes	December 31, 2024 Amount	%	December 31, 2023 Amount	%
	Current assets					
1100	Cash and cash equivalents	6(1)	$ 1,641,783	12	$ 1,891,381	14
1110	Financial assets at fair value through profit or loss - current	6(2)	49,669	-	69,380	1
1136	Current financial assets at amortised cost	6(4)	33,712	-	66,089	1
1140	Contract assets - current	6(23)	70,325	1	68,176	1
1150	Notes receivable, net	6(5)	22,478	-	38,837	-
1170	Accounts receivable, net	6(5)	952,823	7	738,357	5
1180	Accounts receivable due from related parties, net	7	224,881	2	260,123	2
1200	Other receivables	7	39,660	-	1,093	-
1220	Current tax assets		13,804	-	3,416	-
130X	Inventories	6(6)(9)	883,781	6	605,476	4
1410	Prepayments	6(7)(9)	709,037	5	588,446	4
1470	Other current assets		125,761	1	915	-
11XX	**Total current assets**		4,767,714	34	4,331,689	32
	Non-current assets					
1510	Financial assets at fair value through profit or loss - non-current	6(2)	69,041	1	67,789	1
1517	Financial assets at fair value through other comprehensive income - non-current	6(3)	87,824	1	36,959	-
1535	Non-current financial assets at amortised cost	6(4) and 8	201,416	1	199,745	1
1560	Contract assets - non-current	6(23)	51,210	-	42,933	-
1550	Investments accounted for using equity method	6(8)	10,912	-	9,911	-
1600	Property, plant and equipment	6(9) 7 and 8	5,718,856	40	5,916,247	43
1755	Right-of-use assets	6(10) and 7	271,572	2	110,435	1
1760	Investment property, net	6(12) and 8	1,459,475	10	1,549,304	11
1780	Intangible assets	6(13)(32)	723,046	5	631,150	5
1840	Deferred tax assets	6(29)	134,096	1	93,240	1
1930	Long-term notes and accounts receivable	6(5)	297,153	2	267,299	2
1940	Long-term notes and accounts receivable due from related parties	7	7,665	-	8,174	-
1990	Other non-current assets	6(9)(12)(14) and 8	414,477	3	348,552	3
15XX	**Total non-current assets**		9,446,743	66	9,281,738	68
1XXX	**Total assets**		$ 14,214,457	100	$ 13,613,427	100

(Continued)

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Liabilities and equity	Notes	December 31, 2024 Amount	%	December 31, 2023 Amount	%
	Current liabilities					
2100	Short-term borrowings	6(15) and 8	$ 856,515	6	$ 359,075	3
2130	Contract liabilities - current	6(23)	252,250	2	102,379	1
2150	Notes payable		30,969	-	21,216	-
2170	Accounts payable	7	475,566	4	375,894	3
2200	Other payables	6(9)(12)	118,940	1	194,966	1
2230	Current tax liabilities		22,793	-	118,057	1
2250	Provisions for liabilities - current		12,407	-	13,447	-
2280	Lease liabilities - current	7	40,590	-	33,632	-
2320	Long-term liabilities, current portion	6(16)(17) and 8	1,673,348	12	202,546	1
2399	Other current liabilities		10,201	-	4,793	-
21XX	**Total current liabilities**		3,493,579	25	1,426,005	10
	Non-current liabilities					
2527	Contract liabilities - non-current	6(23)	672,241	4	657,915	5
2530	Bonds payable	6(16)(20)	-	-	1,317,066	10
2540	Long-term borrowings	6(9)(17) and 8	2,864,801	20	3,066,933	23
2550	Provisions for liabilities - non-current	6(9)	18,200	-	17,980	-
2570	Deferred tax liabilities	6(29)	107,847	1	99,232	1
2580	Lease liabilities - non-current	7	275,482	2	207,590	1
2600	Other non-current liabilities	6(17)(32)	109,823	1	45,200	-
25XX	**Total non-current liabilities**		4,048,394	28	5,411,916	40
2XXX	**Total liabilities**		7,541,973	53	6,837,921	50
	Equity attributable to owners of the parent					
	Share capital	6(16)(19)(20)				
3110	Common stock		1,668,651	12	1,664,194	12
	Capital surplus	6(16)(19)(21)				
3200	Capital surplus		3,732,745	26	3,716,656	27
	Retained earnings	6(22)				
3310	Legal reserve		469,411	3	427,524	3
3320	Special reserve		385,664	3	387,424	3
3350	Unappropriated retained earnings		441,941	3	648,281	5
	Other equity	6(3)				
3400	Other equity		(395,141)	(3)	(385,664)	(2)
31XX	**Total equity attributable to owners of the parent**		6,303,271	44	6,458,415	48
36XX	**Non-controlling interest**	4(3)	369,213	3	317,091	2
3XXX	**Total equity**		6,672,484	47	6,775,506	50
	Significant contingent liabilities and unrecognised contract commitments	9				
	Significant events after the balance sheet date	11				
3X2X	**Total liabilities and equity**		$ 14,214,457	100	$ 13,613,427	100

The accompanying notes are an integral part of these consolidated financial statements.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS,
EXCEPT FOR EARNINGS PER SHARE AMOUNTS)

	Items	Notes	2024 Amount	2024 %	2023 Amount	2023 %
4000	**Operating revenue**	6(5)(11)(12)(23) and 7	$ 3,600,574	100	$ 3,877,137	100
5000	**Operating costs**	6(6)(9)(10)(12)(18)(19)(28) and 7	(2,841,449)	(79)	(2,808,977)	(72)
5950	**Gross profit**		759,125	21	1,068,160	28
	Operating expenses	6(9)(10)(12)(13)(18)(19)(28) and 7				
6100	Selling expenses		(269,170)	(7)	(218,424)	(6)
6200	General and administrative expenses		(253,287)	(7)	(235,983)	(6)
6450	Impairment gain (expected credit impairment loss)		2,042	-	(277)	-
6000	**Total operating expenses**		(520,415)	(14)	(454,684)	(12)
6900	**Operating profit**		238,710	7	613,476	16
	Non-operating income and expenses					
7100	Interest income	6(4)(10)(24) and 7	26,102	1	20,683	-
7010	Other income	6(11)(12)(17)(25)(32) and 7	53,286	1	7,889	-
7020	Other gains and losses	6(2)(10)(26)	2,260	-	4,779	-
7050	Finance costs	6(27) and 7	(98,352)	(3)	(89,001)	(2)
7060	Share of profit of associates and joint ventures accounted for using equity method	6(8)	1,001	-	1,604	-
7000	**Total non-operating income and expenses**		(15,703)	(1)	(54,046)	(2)
7900	**Profit before income tax**		223,007	6	559,430	14
7950	Income tax expense	6(29)	(40,430)	(1)	(134,192)	(3)
8200	**Profit for the year**		$ 182,577	5	$ 425,238	11
	Other comprehensive income					
	Components of other comprehensive income that will not be reclassified to profit or loss					
8316	Unrealised gains from investments in equity instruments measured at fair value through other comprehensive income	6(3)	$ 2,565	-	$ 7,381	-
	Components of other comprehensive income that will be reclassified to profit or loss					
8361	Financial statements translation differences of foreign operations		15,515	1	(5,682)	-
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	6(29)	5	-	(7)	-
8300	**Other comprehensive income for the year**		$ 18,085	1	$ 1,692	-
8500	**Total comprehensive income for the year**		$ 200,662	6	$ 426,930	11
	Profit attributable to:					
8610	Owners of the parent		$ 168,384	5	$ 418,866	11
8620	Non-controlling interest		$ 14,193	-	$ 6,372	-
	Comprehensive income attributable to:					
8710	Owners of the parent		$ 185,552	6	$ 420,625	11
8720	Non-controlling interest		$ 15,110	-	$ 6,305	-
	Earnings per share (in dollars)					
9750	**Basic earnings per share**	6(30)	$	1.01	$	2.55
9850	**Diluted earnings per share**	6(30)	$	0.98	$	2.26

The accompanying notes are an integral part of these consolidated financial statements.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		Equity attributable to owners of the parent												
		Capital Reserves				Retained Earnings			Other Equity Interest					
	Notes	Common stock	Capital surplus	Employee stock warrants	Others	Legal reserve	Special reserve	Unappropriated retained earnings	Financial statements translation differences of foreign operations	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Others	Total	Non-controlling interest	Total equity
2023														
Balance at January 1, 2023		$ 1,615,531	$ 3,476,727	$ 8,551	$ 59,145	$ 391,867	$ 395,708	$ 581,510	($ 35,386)	($ 352,037)	$ -	$ 6,141,616	$ 261,480	$ 6,403,096
Consolidated net income		-	-	-	-	-	-	418,866	-	-	-	418,866	6,372	425,238
Other comprehensive income (loss)		-	-	-	-	-	-	-	(5,622)	7,381	-	1,759	(67)	1,692
Total comprehensive income (loss)		-	-	-	-	-	-	418,866	(5,622)	7,381	-	420,625	6,305	426,930
Appropriations of 2022 earnings	6(22)													
Legal reserve		-	-	-	-	35,657	-	(35,657)	-	-	-	-	-	-
Cash dividends		-	-	-	-	-	-	(324,722)	-	-	-	(324,722)	-	(324,722)
Reversal of special reserve		-	-	-	-	-	(8,284)	8,284	-	-	-	-	-	-
Conversion of convertible bonds	6(16)(20)	41,933	163,705	-	(3,396)	-	-	-	-	-	-	202,242	-	202,242
Exercise of employee stock options	6(19)(20)	6,730	18,636	(6,998)	-	-	-	-	-	-	-	18,368	-	18,368
Compensation cost of employee stock options	6(19)	-	-	99	-	-	-	-	-	-	-	99	-	99
Compensation cost of employee stock options of subsidiaries	6(19)	-	-	187	-	-	-	-	-	-	-	187	-	187
Employee stock options expired		-	-	(108)	108	-	-	-	-	-	-	-	-	-
Increase in non-controlling interest	6(31)	-	-	-	-	-	-	-	-	-	-	-	49,306	49,306
Balance at December 31, 2023		$ 1,664,194	$ 3,659,068	$ 1,731	$ 55,857	$ 427,524	$ 387,424	$ 648,281	($ 41,008)	($ 344,656)	$ -	$ 6,458,415	$ 317,091	$ 6,775,506
2024														
Balance at January 1, 2024		$ 1,664,194	$ 3,659,068	$ 1,731	$ 55,857	$ 427,524	$ 387,424	$ 648,281	($ 41,008)	($ 344,656)	$ -	$ 6,458,415	$ 317,091	$ 6,775,506
Consolidated net income		-	-	-	-	-	-	168,384	-	-	-	168,384	14,193	182,577
Other comprehensive income		-	-	-	-	-	-	-	14,603	2,565	-	17,168	917	18,085
Total comprehensive income		-	-	-	-	-	-	168,384	14,603	2,565	-	185,552	15,110	200,662
Appropriations of 2023 earnings	6(22)													
Legal reserve		-	-	-	-	41,887	-	(41,887)	-	-	-	-	-	-
Cash dividends		-	-	-	-	-	-	(334,502)	-	-	-	(334,502)	-	(334,502)
Reversal of special reserve		-	-	-	-	-	(1,760)	1,760	-	-	-	-	-	-
Conversion of convertible bonds	6(16)(20)	4,157	15,943	-	(330)	-	-	-	-	-	-	19,770	-	19,770
Exercise of employee stock options	6(19)(20)	300	803	(327)	-	-	-	-	-	-	-	776	-	776
Changes in ownership interests in subsidiaries	6(31)	-	-	-	1,948	-	-	-	-	-	-	1,948	(1,948)	-
Decrease in subsidiaries capital from non-controlling interest	6(31)	-	-	-	-	-	-	-	-	-	-	-	83,053	83,053
Disposal of subsidiaries	6(33)	-	-	-	(1,948)	-	-	(95)	-	-	-	(2,043)	(56,971)	(59,014)
Redemption liabilities of subsidiaries	6(32)	-	-	-	-	-	-	-	-	-	(26,645)	(26,645)	(25,600)	(52,245)
Increase in non-controlling interest		-	-	-	-	-	-	-	-	-	-	-	38,478	38,478
Balance at December 31, 2024		$ 1,668,651	$ 3,675,814	$ 1,404	$ 55,527	$ 469,411	$ 385,664	$ 441,941	($ 26,405)	($ 342,091)	($ 26,645)	$ 6,303,271	$ 369,213	$ 6,672,484

The accompanying notes are an integral part of these consolidated financial statements.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		$ 223,007	$ 559,430
Adjustments			
Adjustments to reconcile profit (loss)			
(Impairment gain) expected credit loss		(2,042)	277
Depreciation charge	6(9)(10)(12)(28)	608,819	572,563
Amortisation charge	6(13)(28)	25,148	21,900
Loss on disposal of property, plant and equipment	6(26)	1,447	1,331
Property, plant and equipment transferred to expenses	6(9)	133	488
Loss (gain) from lease modification	6(26)	7,333	(162)
Interest expense		118,458	104,333
Interest income	6(24)	(26,102)	(20,683)
Dividend income	6(25)	(758)	(1,565)
Government grant income		(1,294)	(856)
Bargain purchase gain	6(25)(32)	(362)	-
Share of profit of associates and joint ventures accounted for using equity method	6(8)	(1,001)	(1,604)
Net gain on financial assets or liabilities at fair value through profit or loss	6(2)(26)	(4,030)	(13,089)
Gain on disposal of subsidiaries	6(26)	(3,534)	-
Amortisation of discount on bonds payable	6(27)	9,235	9,874
Compensation cost of employee stock options	6(19)(28)	-	286
Changes in operating assets and liabilities			
Changes in operating assets			
Financial assets at fair value through profit or loss		22,465	(16,499)
Contract assets		(10,426)	(4,358)
Notes receivable		25,618	4,825
Accounts receivable		(320,082)	(119,686)
Accounts receivable due from related parties		35,751	(2,833)
Other receivables		(38,562)	1,509
Inventories		(255,603)	(76,688)
Prepayments		(108,579)	(11,955)
Other current assets		124,846	11,917
Changes in operating liabilities			
Contract liabilities		148,094	48,653
Notes payable		(5,510)	223
Accounts payable		62,671	48,702
Other payables		(29,880)	20,326
Provisions for liabilities		(2,020)	(2,195)
Other current liabilities		5,292	292
Cash inflow generated from operations		358,840	1,134,756
Dividends received during the year		1,058	1,265
Interest paid during the year		(96,071)	(86,225)
Interest received during the year		26,102	20,683
Income tax paid		(190,562)	(107,891)
Net cash flows from operating activities		99,367	962,588

(Continued)

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2024 AND 2023
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	2024	2023
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of financial assets at fair value through other comprehensive income		($ 48,300)	$ -
Proceeds from disposal of financial assets at amortised cost		30,706	143,647
Decrease in other receivables due from related parties		-	71,000
Acquisition of property, plant and equipment	6(9)	(431,086)	(549,672)
Proceeds from disposal of property, plant and equipment		11,049	1,068
Acquisition of investment properties	6(12)	(44,705)	(29,390)
Increase in refundable deposits		(114,289)	(121,739)
Decrease in refundable deposits		83,738	67,413
Increase in other non-current assets		(67,716)	(7,272)
Net cash flows from acquisition of subsidiaries	6(32)	(39,251)	(49,520)
Net cash flows from the disposal of a subsidiary	6(33)	74,999	-
Acquisition of intangible assets	6(13)	-	(26,000)
Net cash flows used in investing activities		(544,855)	(500,465)
CASH FLOWS FROM FINANCING ACTIVITIES			
Increase in short-term loans	6(34)	2,849,655	2,104,311
Decrease in short-term loans	6(34)	(2,352,215)	(2,057,956)
Payments of lease liabilities	6(34)	(41,028)	(33,510)
Proceeds from long-term debt	6(34)	197,615	515,935
Repayments of long-term debt	6(34)	(211,704)	(271,848)
Increase in guarantee deposits received	6(34)	16,898	6,874
Decrease in guarantee deposits received	6(34)	(5,757)	(3,421)
Exercise of employee stock options		776	18,368
Payment of cash dividends	6(22)	(334,502)	(324,722)
Change in non-controlling interest	6(31)	83,053	3,921
Dividends paid to non-controlling interests		(14,553)	-
Net cash flows provided by (used in) financing activities		188,238	(42,048)
Effect of changes in foreign currency exchange rates on cash and cash equivalents		7,652	(1,543)
(Decrease) increase in cash and cash equivalents		(249,598)	418,532
Cash and cash equivalents at beginning of year		1,891,381	1,472,849
Cash and cash equivalents at end of year		$ 1,641,783	$ 1,891,381

The accompanying notes are an integral part of these consolidated financial statements.

【Attachment 8】

CHC Healthcare Group

Comparison Table of Revised Articles of "Articles of Incorporation"

Article before revision	Article after revision	Explanation
Article 24-1 When allocating the profit of current year (profit before tax and compensations for employees and remunerations for directors), accumulated losses shall be first covered, and then set aside no less than 0.05% of the balance as compensations for employees and no more than 5% as remunerations for directors. Compensations for employees and remunerations for directors mentioned above shall be conducted after a resolution made by majority of directors present at a meeting attended by more than two thirds of directors and shall also be reported to the shareholders' meeting. Compensations for employees shall be paid by either shares or cash. The employees to receive compensations shall include certain qualified employees from parent company or affiliate companies and the rules of distribution shall be made by the Chairman.	Article 24-1 When allocating the profit of current year (profit before tax and compensations for employees and remunerations for directors), accumulated losses shall be first covered, and then set aside no less than 0.05% of the balance as compensations for employees and no more than 5% as remunerations for directors. Of the aforementioned employees' compensation amount, no less than 20% shall be allocated to junior employeess. Compensations for employees and remunerations for directors mentioned ~~above~~ in the preceding two paragraphs shall be conducted after a resolution made by majority of directors present at a meeting attended by more than two thirds of directors and shall also be reported to the shareholders' meeting. Compensations for employees shall be paid by either shares or cash. The employees to receive compensations shall include certain qualified employees from parent company or affiliate companies and the rules of distribution shall be made by the Chairman.	Revise wording as appropriate in accordance with the revision of relevant laws and regulations.
Article 28 The Article was enacted on Nov. 25, 2009 and amended on Nov. 28, 2009 for the first time, on Jan 15, 2010 for the second time, on Feb. 10, 2010 for the third time, on Jun. 30, 2011 for the fourth time, on Jan. 6, 2012 for the fifth time, on Jun. 14, 2013 for the sixth time, on Jun. 13, 2016 for the seventh time, on Jun. 13, 2017 for the eighth time, on Jun. 12, 2019 for the ninth time, on Jun. 15, 2022 for the tenth time.	Article 28 The Article was enacted on Nov. 25, 2009 and amended on Nov. 28, 2009 for the first time, on Jan 15, 2010 for the second time, on Feb. 10, 2010 for the third time, on Jun. 30, 2011 for the fourth time, on Jan. 6, 2012 for the fifth time, on Jun. 14, 2013 for the sixth time, on Jun. 13, 2016 for the seventh time, on Jun. 13, 2017 for the eighth time, on Jun. 12, 2019 for the ninth time, on Jun. 15, 2022 for the tenth time, on Jun.4, 2025 for the eleventh time.	Add amending date.

【Attachment 9】

CHC Healthcare Group

Concurrent Positions to be Released from Non-Competition Restrictions on Directors

Directors	Concurrent positions to be released from non-competition restrictions
Vice chairman **Tien-Ying, Lee**	Director and General Manager, S&S Healthcare Holding Ltd.
	Chairman and representative of juristic person director, Chao Ying International Co., Ltd.
	Director, Central Taiwan University of Science and Technology